KACTUS X Biocytogen AACR Dinner Party

Join KACTUS and Biocytogen for an invite-only dinner during the AACR Annual Conference.

You're invited to an exclusive evening of connection and conversation at the Biocytogen x KACTUS AACR Dinner Party. Join us in Chicago during the American Association for Cancer Research Annual Meeting for a relaxed, insightful gathering focused on accelerating drug development and advancing research.

Whether you're eager to explore cutting-edge biotech innovations or exchange ideas with fellow scientists and industry leaders, this dinner offers the perfect setting to connect.

A quick 7-minute walk from the AACR convention center to enjoy dinner and drinks with us!

Event Information

• Date: April 28
• Time: 6:00 pm – 9:00 pm
• Location: Il Culaccino, 2134 S. Indiana Ave. Chicago, IL 60616

Why Attend?

• Networking: Engage with thought leaders, collaborators, and peers from across the biotech and pharmaceutical landscape.
• Insights: Discuss current trends, breakthrough technologies, and shared challenges shaping the future of cancer research and drug discovery.
• Dinner: Enjoy a curated menu inspired by local Chicago flavors and international cuisine.

RSVP Today

Space is limited and fills quickly—reserve your seat now to be part of this invite-only event!

About KACTUS

KACTUS is a leading biotechnology company specializing in the design and production of recombinant proteins and enzymes. Our comprehensive catalog selection of 3000+ ready-made recombinant proteins including various targets, species, tags, and labels curated to help advance antibody drug discovery, immunotherapy, gene therapy, and RNA therapeutics through superior protein and enzyme engineering. Additionally, our expertise with difficult recombinant protein expressions including transmembrane proteins, MHCs, and nanodiscs makes us a leading service provider in custom protein expression. With in-house GMP manufacturing facilities and a certified quality system, KACTUS is your reliable partner for proteins from early stage research through clinical manufacturing.

About Biocytogen

Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).